Asia Pacific Pharma ADMET Testing Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Testing Type (In Vivo ADMET Testing, In Vitro ADMET Testing, and In Silico ADMET Testing), Technology (Cell Culture, High Throughput, Molecular Imaging, and OMICS Technology), and Application (Systemic Toxicity, Renal Toxicity, Hepatotoxicity, Neurotoxicity, and Others)
The pharma ADMET testing market in Asia Pacific is expected to grow from US$ 1,586.66 million in 2022 to US$ 2,978.23 million by 2028. It is estimated to grow at a CAGR of 11.1% from 2022 to 2028.
Over the last decade, the pharmaceutical industry has witnessed many transformational trends and innovations that have the potential to improve medicines available on the market worldwide rapidly. In the last 10 years, the influence of AI and Big Data analytics on disease diagnosis and treatment and a shift toward preventing life-threatening conditions rather than curing them have led to the evolution of healthcare. With the continuous evolution of science and technology, exciting developments in the field of high throughput ADME (HT-ADME) research are highly anticipated in the next decade. The emerging fields of ADME sciences will find their way into ADME screening studies from the perspective of assay repertoire.
The novel, physiologically appropriate in-vitro micro-physiological systems (MPS), such as 3D tissue cultures and organ(s)-on-a-chip, are likely to make their way in the improvement efforts for in-vitro in-vivo translation (IVIVT). The use of endogenous probes (basic biomarkers) for in vivo transporter drug-drug interaction (DDI) investigations is coming up as another trend in ADME testing, as this approach can lower pill burden and help obtain transporter DDI data from a standard phase I trial. The HT-ADME screening of innovative drug delivery systems is yet another example. The field is prepared to undertake early ADME screening of novel modalities, such as protein degraders, antisense oligonucleotides (ASOs), antibody-drug conjugates (ADCs), and biologics, in addition to small molecules and peptides. Although the ADME studies for these modalities are still developing, an increasing number of HT-ADME format assays are anticipated to go online to support ongoing scientific research. With the long history of HT-ADME operation in many companies and the resulting wealth of ADME data that can be “mined,” the development of in silico models to predict ADME properties has long been acknowledged as the obvious next step for HT-ADME screening. The HT-ADME dataset of any big pharmaceutical company could include test findings from numerous compounds, in contrast to many ADME prediction models described in the literature that employ a training set of a smaller number of compounds. Due to their size, these datasets can be the best training sets for model building. ADME features have long been studied using computational chemistry methods designed to create quantitative structure-activity relationship (QSAR) models. Models for clearance, permeability, and DDI potentials have recently been developed using various machine learning (ML) techniques. Hit triaging from lead discovery screens and the design-make-test cycles of lead optimization in drug discovery, among others, can be employed to obtain predictive ADME models due to the recent rapid developments in ML methodologies and the large size of the HT-ADME datasets available for use as training sets. These top trends will transform the pharmaceutical industry and can have short-term and long-term benefits on the ADMET testing market.
Asia Pacific Pharma ADMET Testing Market Revenue and Forecast to 2028 (US$ Million)
Asia Pacific Pharma ADMET Testing Market Segmentation
The Asia Pacific pharma ADMET testing market is segmented by testing type, technology, application, and country. Based on testing type, the market is segmented into in vivo ADMET testing, in vitro ADMET testing, and in silico ADMET testing. The in vivo ADMET testing segment is dominating the market in 2022. Based on technology, the market is segmented into cell culture, high throughput, molecular imaging, and OMICS technology. The cell culture segment is dominating the market in 2022. Based on application, the market is segmented into systemic toxicity, renal toxicity, hepatotoxicity, neurotoxicity, and others. The systemic toxicity segment is dominating the market in 2022. Based on country, the market is segmented into China, Japan, India, Australia, South Korea, and the rest of Asia Pacific. Further, China dominated the market in 2022.
A few key players dominating the Asia Pacific pharma ADMET testing market are Agilent Technologies, Inc.; Bio-Rad Laboratories, Inc.; Biovia (Dassault Systèmes); Charles River Laboratories; IQVIA Inc.; MERCK KGaA; Promega Corporation; and Wuxi AppTec.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 APAC Pharma ADMET Testing Market – By Testing Type
1.3.2 APAC Pharma ADMET Testing Market – By Technology
1.3.3 APAC Pharma ADMET Testing Market – By Application
1.3.4 APAC Pharma ADMET Testing Market – By Country
2. APAC Pharma ADMET Testing Market– Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. APAC Pharma ADMET Testing Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 APAC – PEST Analysis
4.3 Expert Opinion
5. APAC Pharma ADMET Testing Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 High Rate of Late-Stage Drug Failure
5.1.2 Increasing Number of Product Approvals and Launches
5.2 Market Restraints
5.2.1 High Cost of ADME Testing Studies
5.3 Market Opportunities
5.3.1 Automation and Advancements in ADME Testing
5.4 Future Trends
5.4.1 The Advent of High-Throughput Screening
5.5 Impact Analysis
6. Pharma ADMET Testing Market– APAC Analysis
6.1 APAC Pharma ADMET Testing Market Revenue Forecast and Analysis
7. APAC Pharma ADMET Testing Market– By Testing Type
7.1 Overview
7.2 APAC Pharma ADMET Testing Market, By Testing Type 2022 & 2028 (%)
7.3 In Vivo ADMET Testing
7.3.1 Overview
7.3.2 In Vivo ADMET Testing - Revenue and Forecast to 2028 (US$ Million)
7.4 In Vitro ADMET Testing
7.4.1 Overview
7.4.2 In Vitro ADMET Testing - Revenue and Forecast to 2028 (US$ Million)
7.5 In Silico ADMET Testing
7.5.1 Overview
7.5.2 In Silico ADMET Testing - Revenue and Forecast to 2028 (US$ Million)
8. APAC Pharma ADMET Testing Market– By Technology
8.1 Overview
8.2 APAC Pharma ADMET Testing Market, By Technology 2022 & 2028 (%)
8.3 Cell Culture
8.3.1 Overview
8.3.2 Cell Culture - Market Revenue and Forecast to 2028 (US$ Million)
8.4 High Throughput
8.4.1 Overview
8.4.2 High Throughput - Market Revenue and Forecast to 2028 (US$ Million)
8.5 Molecular Imaging
8.5.1 Overview
8.5.2 Molecular Imaging - Market Revenue and Forecast to 2028 (US$ Million)
8.6 OMICS Technology
8.6.1 Overview
8.6.2 OMICS Technology - Market Revenue and Forecast to 2028 (US$ Million)
9. APAC Pharma ADMET Testing Market– By Application
9.1 Overview
9.2 APAC Pharma ADMET Testing Market, By Application 2022 & 2028 (%)
9.3 Systemic Toxicity
9.3.1 Overview
9.3.2 Systemic Toxicity - Market Revenue and Forecasts to 2028 (US$ Million)
9.4 Renal Toxicity
9.4.1 Overview
9.4.2 Renal Toxicity - Market Revenue and Forecasts to 2028 (US$ Million)
9.5 Hepatotoxicity
9.5.1 Overview
9.5.2 Hepatotoxicity - Market Revenue and Forecasts to 2028 (US$ Million)
9.6 Neurotoxicity
9.6.1 Overview
9.6.2 Neurotoxicity - Market Revenue and Forecasts to 2028 (US$ Million)
9.7 Others
9.7.1 Overview
9.7.2 Others - Revenue and Forecasts to 2028 (US$ Million)
10. APAC Pharma ADMET Testing Market– Country Analysis
10.1 APAC Pharma ADMET Testing Market Revenue and Forecasts to 2028
10.1.1 Overview
10.1.2 APAC: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Country (%)
10.1.2.1 China: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
10.1.2.1.1 Overview
10.1.2.1.2 China: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
10.1.2.1.3 China: Pharma ADMET Testing Market, by Testing Type, 2019–2028 (US$ Million)
10.1.2.1.4 China: Pharma ADMET Testing Market, by Technology, 2019–2028 (US$ Million)
10.1.2.1.5 China: Pharma ADMET Testing Market, by Application, 2019–2028 (US$ Million)
10.1.2.2 Japan: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
10.1.2.2.1 Overview
10.1.2.2.2 Japan: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
10.1.2.2.3 Japan: Pharma ADMET Testing Market, by Testing Type, 2019–2028 (US$ Million)
10.1.2.2.4 Japan: Pharma ADMET Testing Market, by Technology, 2019–2028 (US$ Million)
10.1.2.2.5 Japan: Pharma ADMET Testing Market, by Application, 2019–2028 (US$ Million)
10.1.2.3 India: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
10.1.2.3.1 Overview
10.1.2.3.2 India: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
10.1.2.3.3 India: Pharma ADMET Testing Market, by Testing Type, 2019–2028 (US$ Million)
10.1.2.3.4 India: Pharma ADMET Testing Market, by Technology, 2019–2028 (US$ Million)
10.1.2.3.5 India: Pharma ADMET Testing Market, by Application, 2019–2028 (US$ Million)
10.1.2.4 South Korea: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
10.1.2.4.1 Overview
10.1.2.4.2 South Korea: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
10.1.2.4.3 South Korea: Pharma ADMET Testing Market, by Testing Type, 2019–2028 (US$ Million)
10.1.2.4.4 South Korea: Pharma ADMET Testing Market, by Technology, 2019–2028 (US$ Million)
10.1.2.4.5 South Korea: Pharma ADMET Testing Market, by Application, 2019–2028 (US$ Million)
10.1.2.5 Australia: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
10.1.2.5.1 Overview
10.1.2.5.2 Australia: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
10.1.2.5.3 Australia: Pharma ADMET Testing Market, by Testing Type, 2019–2028 (US$ Million)
10.1.2.5.4 Australia: Pharma ADMET Testing Market, by Technology, 2019–2028 (US$ Million)
10.1.2.5.5 Australia: Pharma ADMET Testing Market, by Application, 2019–2028 (US$ Million)
10.1.2.6 Rest of APAC: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.6.1 Overview
10.1.2.6.2 Rest of APAC: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.6.3 Rest of APAC: Pharma ADMET Testing Market, by Testing Type, 2019–2028 (US$ Million)
10.1.2.6.4 Rest of APAC: Pharma ADMET Testing Market, by Technology, 2019–2028 (US$ Million)
10.1.2.6.5 Rest of APAC: Pharma ADMET Testing Market, by Application, 2019–2028 (US$ Million)
11. APAC Pharma ADMET Testing Market–Industry Landscape
11.1 Overview
11.2 Organic Developments
11.2.1 Overview
11.3 Inorganic Developments
11.3.1 Overview
12. Company Profiles
12.1 Charles River Laboratories
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 WuXi AppTec
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Promega Corporation
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Sigma-Aldrich (MERCK KGaA)
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Agilent Technologies, Inc.
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Biovia (Dassault Systèmes)
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Bio-Rad Laboratories, Inc.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 IQVIA Inc.
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. APAC Pharma ADMET Testing Market –Revenue and Forecast to 2028 (US$ Million)
Table 2. China: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)
Table 3. China: Pharma ADMET Testing Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
Table 4. China: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 5. Japan: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)
Table 6. Japan: Pharma ADMET Testing Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
Table 7. Japan: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 8. India: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)
Table 9. India: Pharma ADMET Testing Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
Table 10. India: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 11. South Korea: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)
Table 12. South Korea: Pharma ADMET Testing Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
Table 13. South Korea: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 14. Australia: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)
Table 15. Australia: Pharma ADMET Testing Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
Table 16. Australia: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 17. Rest of APAC Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)
Table 18. Rest of APAC: Pharma ADMET Testing Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
Table 19. Rest of APAC: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 20. Organic Developments Done by Companies
Table 21. Inorganic Developments Done by Companies
Table 22. Glossary of Terms
LIST OF FIGURES
Figure 1. APAC Pharma ADMET Testing Market Segmentation
Figure 2. APAC Pharma ADMET Testing Market, By Country
Figure 3. APAC Pharma ADMET Testing Market Overview
Figure 4. In vivo ADMET Testing Segment Held Largest Share of Testing Type Segment in APAC Pharma ADMET Testing Market
Figure 5. China is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. APAC: PEST Analysis
Figure 7. Expert Opinion
Figure 8. APAC Pharma ADMET Testing Market Impact Analysis of Driver and Restraints
Figure 9. APAC Pharma ADME Testing Market– Revenue Forecast and Analysis – 2022 - 2028
Figure 10. APAC Pharma ADMET Testing Market, by Testing Type 2022 & 2028 (%)
Figure 11. In Vivo ADMET Testing - Revenue and Forecasts to 2028 (US$ Million)
Figure 12. In Vitro ADMET Testing - Revenue and Forecasts to 2028 (US$ Million)
Figure 13. In Silico ADMET Testing - Revenue and Forecasts to 2028 (US$ Million)
Figure 14. APAC Pharma ADMET Testing Market, by Technology 2022 & 2028 (%)
Figure 15. Cell Culture - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 16. High Throughput - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 17. Molecular Imaging - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 18. OMICS Technology - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 19. APAC Pharma ADMET Testing Market, by Application 2022 & 2028 (%)
Figure 20. Systemic Toxicity - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 21. Renal Toxicity - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 22. Hepatotoxicity - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 23. Neurotoxicity - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 24. Others - Revenue and Forecasts to 2028 (US$ Million)
Figure 25. APAC Pharma ADMET Testing Market Overview, by Country (2022)
Figure 26. APAC: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Country (%)
Figure 27. China: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
Figure 28. Japan: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
Figure 29. India: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
Figure 30. South Korea: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
Figure 31. Australia: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
Figure 32. Rest of APAC: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Biovia (Dassault Systèmes)
- Charles River Laboratories
- IQVIA Inc.
- MERCK KGaA
- Promega Corporation
- Wuxi AppTec
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Asia Pacific pharma ADMET testing market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific pharma ADMET testing market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the pharma ADMET testing market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution